Chicago’s Morning Answer host Dan Proft welcomed back Dr. Michael Huber, the developer of the dietary supplement Virogo, for a conversation that began with Huber’s background before turning to the product itself. Huber said he started working in medical research at 15 years old, first on an obesity study at Northwestern University, before spending time observing cardiovascular surgeons who were working on an implantable artificial lung and trachea. He said that by his late teens he was contributing his own design changes to the artificial trachea project and presenting the work at a conference in Chicago. Huber said that early exposure led him first into chiropractic care, which he described as a preventive approach to medicine, and later into nutrition, before he enrolled in medical school in his fifties and became a licensed physician.
Huber told Proft that the idea for Virogo grew out of conversations with a friend, an internist in Jacksonville, Florida, during the surge of the COVID-19 Delta variant. Huber said his friend treated patients differently than hospital protocols at the time recommended and, according to Huber, saw better outcomes than colleagues who followed what Huber called the guidance associated with Dr. Anthony Fauci. Huber said the two began combining vitamins, herbs and other supplements, which he referred to as “nutraceuticals,” together with the drugs hydroxychloroquine and ivermectin, and said that in his account, patients treated this way avoided hospitalization. It’s worth noting that the Food and Drug Administration and mainstream medical guidance during the pandemic did not support hydroxychloroquine or ivermectin as COVID-19 treatments, and Huber’s account of patient outcomes reflects his own characterization rather than a clinical study. Huber said the eventual decision to combine the various supplements into a single liquid formulation, rather than requiring patients to take dozens of pills, was partly driven by wanting to engage what he described as immune-related receptors in the mouth before the product reaches the stomach.
Asked how Virogo works, Huber described it as a blend of ingredients that he said act on different parts of a virus and a cell’s receptors simultaneously, which he characterized as giving it multiple mechanisms for inhibiting viral entry into cells, in contrast to single-mechanism antiviral drugs. He also said regular use is intended to reduce inflammation associated with conditions such as diabetes, hypertension, obesity and digestive issues, and said he believes the product may help protect organs, including the kidneys, heart, liver and pancreas, from damage associated with those conditions. Huber was careful to say the product is not a treatment or cure for diseases like diabetes or heart disease, but said he views it as supporting the body against the effects of chronic inflammation. These are characterizations offered by Huber as the product’s developer rather than claims that have been independently verified, and, like other dietary supplements, Vyrogo has not been evaluated or approved by the FDA for treating or preventing any disease.
On safety, Huber said the most common complaint from users has been nausea, which he attributed to taking the product on an empty stomach, and said he was not aware of other side effects reported by customers over the roughly two and a half years the product has been on the market, aside from possible allergic reactions to individual ingredients. He also relayed an anecdote from a listener who told him he regained his sense of smell within days of starting the supplement, a case Huber said he could not explain. Huber directed listeners to myvirogo.com and said Chicago’s Morning Answer listeners could use the promotional code Dan40 for 40 percent off purchases made through the end of the week.